Table 2.
Plasma pharmacokinetic parameters of 100 mg posaconazole under fasted conditionsa
| Formulation | AUC0–t (ng · h/ml) | AUC0–∞ (ng · h/ml) | Cmax (ng/ml) | Tmaxb (h) | t1/2 (h) | CL/F (liters/h) | V/F (liters) |
|---|---|---|---|---|---|---|---|
| Oral suspension | 2,970 (50) | 3,420 (44)c | 84.0 (62) | 4.00 (2.00, 8.00) | 29.2 (31)c | 34.0 (38)c | 1,450 (54)c |
| Tablet A | 11,400 (26) | 11,700 (26) | 385 (28) | 5.00 (3.00, 6.00) | 26.1 (28) | 9.16 (29) | 345 (45) |
| Tablet B | 11,000 (22) | 11,300 (22) | 358 (23) | 5.00 (2.00, 8.00) | 25.0 (25) | 9.25 (22) | 331 (34) |
| Capsule | 10,700 (26) | 11,000 (25) | 335 (27) | 5.00 (4.00, 8.00) | 25.1 (27) | 9.67 (26) | 349 (36) |
a
Data are arithmetic means (percent CV) for 16 subjects. AUC0–t, area under the curve from time zero to the time of the final quantifiable sample; AUC0–∞, area under the curve from time zero to infinity; CL/F, apparent total body clearance; Cmax, maximum plasma concentration; CV, coefficient of variation; t1/2, terminal-phase half-life; Tmax, time to Cmax; V/F, apparent volume of distribution.
b
Data represent median (minimum, maximum).
c
n = 15.